1. Home
  2. MATH vs CGEN Comparison

MATH vs CGEN Comparison

Compare MATH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$2.45

Market Cap

145.4M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.83

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
CGEN
Founded
2015
1993
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.4M
143.1M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
MATH
CGEN
Price
$2.45
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
46.5K
437.5K
Earning Date
03-06-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$44,567,257.00
$6,903,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$231.15
P/E Ratio
$5.85
N/A
Revenue Growth
165.86
N/A
52 Week Low
$1.25
$1.13
52 Week High
$4.17
$2.66

Technical Indicators

Market Signals
Indicator
MATH
CGEN
Relative Strength Index (RSI) 48.09 65.73
Support Level $2.28 $1.43
Resistance Level $2.50 $1.73
Average True Range (ATR) 0.16 0.08
MACD 0.03 0.03
Stochastic Oscillator 82.33 91.67

Price Performance

Historical Comparison
MATH
CGEN

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: